High Tower Advisors, LLC Editas Medicine, Inc. Transaction History

High Tower Advisors, LLC

  • $68.3 Billion
  • Q3 2024

A detailed history of High Tower Advisors, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 13,345 shares of EDIT stock, worth $32,161. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,345
Previous 16,228 17.77%
Holding current value
$32,161
Previous $75,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$3.39 - $5.96 $9,773 - $17,182
-2,883 Reduced 17.77%
13,345 $45,000
Q2 2024

Aug 13, 2024
BUY
$4.67 - $7.28 $3,782 - $5,896
810 Added 5.25%
16,228 $75,000
Q1 2024

May 06, 2024
SELL
$7.03 - $11.07 $10,383 - $16,350
-1,477 Reduced 8.74%
15,418 $114,000
Q4 2023

Feb 12, 2024
SELL
$6.25 - $11.11 $24,387 - $43,351
-3,902 Reduced 18.76%
16,895 $171,000
Q3 2023

Nov 08, 2023
SELL
$6.92 - $9.31 $7,881 - $10,604
-1,139 Reduced 5.19%
20,797 $162,000
Q2 2023

Aug 14, 2023
BUY
$6.36 - $11.47 $27,933 - $50,376
4,392 Added 25.03%
21,936 $180,000
Q1 2023

May 11, 2023
SELL
$7.03 - $11.53 $703 - $1,153
-100 Reduced 0.57%
17,544 $127,000
Q4 2022

Feb 08, 2023
BUY
$8.32 - $13.21 $27,480 - $43,632
3,303 Added 23.03%
17,644 $156,000
Q3 2022

Nov 09, 2022
BUY
$12.16 - $19.42 $174,386 - $278,502
14,341 New
14,341 $174,000
Q1 2022

May 12, 2022
SELL
$14.08 - $27.63 $151,810 - $297,906
-10,782 Closed
0 $0
Q4 2021

Feb 10, 2022
SELL
$26.55 - $40.57 $643,837 - $983,822
-24,250 Reduced 69.22%
10,782 $284,000
Q3 2021

Nov 12, 2021
SELL
$39.27 - $72.94 $916,169 - $1.7 Million
-23,330 Reduced 39.97%
35,032 $1.44 Million
Q2 2021

Aug 06, 2021
BUY
$31.29 - $56.64 $761,755 - $1.38 Million
24,345 Added 71.57%
58,362 $3.31 Million
Q1 2021

May 10, 2021
BUY
$39.71 - $90.58 $367,079 - $837,321
9,244 Added 37.31%
34,017 $1.43 Million
Q4 2020

Feb 10, 2021
SELL
$27.07 - $84.35 $15,213 - $47,404
-562 Reduced 2.22%
24,773 $1.73 Million
Q3 2020

Nov 13, 2020
BUY
$28.06 - $37.16 $218,026 - $288,733
7,770 Added 44.24%
25,335 $714,000
Q2 2020

Aug 10, 2020
BUY
$18.5 - $34.34 $120,805 - $224,240
6,530 Added 59.18%
17,565 $524,000
Q1 2020

May 21, 2020
BUY
$14.88 - $32.78 $164,200 - $361,727
11,035 New
11,035 $215,000
Q3 2019

Nov 12, 2019
SELL
$22.49 - $26.81 $418,741 - $499,175
-18,619 Closed
0 $0
Q2 2019

Aug 13, 2019
BUY
$20.48 - $27.76 $28,098 - $38,086
1,372 Added 7.96%
18,619 $462,000
Q1 2019

May 15, 2019
BUY
$19.43 - $26.41 $335,109 - $455,493
17,247 New
17,247 $423,000
Q4 2018

Feb 14, 2019
SELL
$18.19 - $31.79 $125,074 - $218,588
-6,876 Closed
0 $0
Q3 2018

Nov 09, 2018
BUY
$27.65 - $38.39 $190,121 - $263,969
6,876 New
6,876 $219,000

Others Institutions Holding EDIT

# of Institutions
247
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $166M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email